Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1973 1
1974 2
1977 4
1980 2
1985 2
1986 1
1987 1
1990 1
1991 2
1992 2
1993 1
1994 2
1995 1
1996 1
1997 3
1998 2
1999 4
2000 1
2001 2
2003 4
2004 2
2005 3
2007 1
2008 13
2009 4
2010 11
2011 11
2012 9
2013 7
2014 12
2015 14
2016 5
2017 1
2018 2
2020 1
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial.
Esteban-Cantos A, Rodríguez-Centeno J, Barruz P, Alejos B, Saiz-Medrano G, Nevado J, Martin A, Gayá F, De Miguel R, Bernardino JI, Montejano R, Mena-Garay B, Cadiñanos J, Florence E, Mulcahy F, Banhegyi D, Antinori A, Pozniak A, Wallet C, Raffi F, Rodés B, Arribas JR; NEAT001/ANRS143 Study Group. Esteban-Cantos A, et al. Among authors: banhegyi d. Lancet HIV. 2021 Apr;8(4):e197-e205. doi: 10.1016/S2352-3018(21)00006-0. Lancet HIV. 2021. PMID: 33794182
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
Dickinson L, Gurjar R, Stöhr W, Bonora S, Owen A, D'Avolio A, Cursley A, Molina JM, Fäetkenheuer G, Vandekerckhove L, Di Perri G, Pozniak A, Richert L, Raffi F, Boffito M; NEAT001/ANRS143 Study Group. Dickinson L, et al. J Antimicrob Chemother. 2020 Mar 1;75(3):628-639. doi: 10.1093/jac/dkz479. J Antimicrob Chemother. 2020. PMID: 31754703 Clinical Trial.
HIV care in Central and Eastern Europe: How close are we to the target?
Gokengin D, Oprea C, Begovac J, Horban A, Zeka AN, Sedlacek D, Allabergan B, Almamedova EA, Balayan T, Banhegyi D, Bukovinova P, Chkhartishvili N, Damira A, Deva E, Elenkov I, Gashi L, Gexha-Bunjaku D, Hadciosmanovic V, Harxhi A, Holban T, Jevtovic D, Jilich D, Kowalska J, Kuvatova D, Ladnaia N, Mamatkulov A, Marjanovic A, Nikolova M, Poljak M, Rüütel K, Shunnar A, Stevanovic M, Trumova Z, Yurin O. Gokengin D, et al. Among authors: banhegyi d. Int J Infect Dis. 2018 May;70:121-130. doi: 10.1016/j.ijid.2018.03.007. Epub 2018 Mar 14. Int J Infect Dis. 2018. PMID: 29550449 Free article.
Infection-related and -unrelated malignancies, HIV and the aging population.
Shepherd L, Borges Á, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J, Karpov I, Kirk O, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD. Shepherd L, et al. HIV Med. 2016 Sep;17(8):590-600. doi: 10.1111/hiv.12359. Epub 2016 Feb 18. HIV Med. 2016. PMID: 26890156 Free article.
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Mocroft A, et al. Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17. Lancet HIV. 2016. PMID: 26762990 Clinical Trial.
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702926 Free article. Clinical Trial.
132 results